Irinotecan: summary and future directions.
Johnson
D H
DH
Division of Hematology and Oncology, Vanderbilt University Medical School, The Vanderbilt Clinic, Nashville, TN 37232-5536, USA. david.johnson@mcmail.vanderbilt
D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000401:mortality; D003131:Combined Modality Therapy; D005544:Forecasting; D006801:Humans; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000188:drug therapy*; D016019:Survival Analysis; D014481:United States
D000972:Antineoplastic Agents, Phytogenic; D000077146:Irinotecan; D002166:Camptothecin